Cody Barnett
Gastroenterology · Mobile, ALNPI 1477642890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 691 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 24.3% of the total.
Across 691 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$690
- Gilead$524
- Bristol Myers Squibb$520
- plus $3K from 28 others
Across 12 payments — averaging $967.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
What the payments were for
- Food & beverage$10,10598%
- Education$2072%
- Gifts$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 173 | $2,512 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 177 | $1,770 |
| Johnson & Johnson | 71 | $1,072 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $690 |
| Gilead | 29 | $524 |
| Bristol Myers Squibb | 35 | $520 |
| Ironwood Pharmaceuticals, Inc | 18 | $292 |
| Madrigal Pharmaceuticals | 8 | $277 |
| Sanofi | 10 | $272 |
| Axonics, Inc. | 3 | $243 |
| Daiichi Sankyo Inc. | 14 | $241 |
| Ardelyx, Inc. | 14 | $223 |
| Lilly USA, LLC | 11 | $195 |
| Braintree Laboratories, Inc. | 11 | $186 |
| Intercept Pharmaceuticals, Inc. | 10 | $157 |
| QOL Medical, LLC | 7 | $148 |
| Merck | 8 | $142 |
| Pfizer | 8 | $126 |
| Shionogi Inc | 6 | $116 |
| Phathom Pharmaceuticals, Inc. | 7 | $100 |
| Nestle Healthcare Nutrition Inc. | 4 | $95 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| UCB, Inc. | 4 | $70 |
| Medtronic | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 3 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Redhill Biopharma Inc. | 2 | $32 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Organon | 2 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Celltrion USA Inc. | 1 | $19 |
| Fujifilm Healthcare Americas Corporation | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$113
- Axonics r-SNM System$113
How this compares
$10,343 in reported general payments places this provider in the 80th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 20 | $559,543 |
| LinzessLinaclotide | 229 | $220,543 |
| OcalivaObeticholic Acid | 13 | $123,294 |
| RemicadeInfliximab | 18 | $122,376 |
| Dupixent PenDupilumab | 12 | $88,730 |
| TrulancePlecanatide | 71 | $64,930 |
| IbsrelaTenapanor Hcl | 29 | $49,644 |
| XifaxanRifaximin | 16 | $36,865 |
| CreonLipase/Protease/Amylase | 14 | $34,961 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 563 | $34,577 |
| MovantikNaloxegol Oxalate | 44 | $33,568 |
| VemlidyTenofovir Alafenamide | 14 | $31,161 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 72 | $12,219 |
| Mesalamine | 22 | $9,899 |
| Alosetron Hcl | 14 | $9,652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $1,072 | $681,91938 claims |
| AbbVieLinzess, Creon | $2,512 | $255,504243 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $157 | $123,29413 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Xifaxan | $1,770 | $101,79587 claims |
| Ardelyx, Inc.Ibsrela | $223 | $49,64429 claims |
| Redhill Biopharma Inc.Movantik | $32 | $33,56844 claims |
| GileadVemlidy | $524 | $31,16114 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $42 | $12,21972 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $100 | $7,22211 claims |
| Braintree Laboratories, Inc.Sutab | $186 | $1,94312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Mobile
- Jack DipalmaMobile$903K
- Phillip HendersonMobile$462K
- William SonnierMobile$178K
- Jorge HerreraMobile$167K
- Matthew EvesMobile$46K
- Michael SandersMobile$25K
- Susan FleetMobile$15K
- Jonathan SiegelMobile$15K
- Panayiotis GrevenitisMobile$11K
- Mason AdamsMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.